How many billions is enough? Prioritizing profits over patients with cystic fibrosis

McGarry and colleagues criticize Vertex pharmaceuticals, the sole manufacturer of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, for drastically decreasing its copayment assistance programs and call for specific measures to protect access to life-changing medications for CF patients.